Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges

• Egile Nagusiak: Marie Brevet (Egilea), Zaibo Li (Egilea), Anil Parwani (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

For the past 2 decades, pathologists have been accustomed to reporting the HER2 status of breast cancer as either positive or negative, based on HER2 IHC. Today, however, there is a clinical imperative to employ a 3-tier approach to interpreting HER2 IHC that can also identify tumours categorised as...